Tempest Therapeutics Inc (TPST) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-0.77x
Tempest Therapeutics Inc (TPST) has a Cash Flow-to-Debt Ratio of -0.77x as of March 2026, meaning its operating cash flow of $-7.60 Million could theoretically repay -1% of its total liabilities ($9.93 Million) in one year. See TPST financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.77x
Operating CF / Total Liabilities
Operating Cash Flow
$-7.60 Million
USD
Total Liabilities
$9.93 Million
USD
Data as of
Mar 2026
Most recent filing
Tempest Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Tempest Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see TPST cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Tempest Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Tempest Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-26.82 Million | $10.26 Million | ▼ -76.9% |
| 2024 | -1.48x | $-33.03 Million | $22.36 Million | ▼ -34.1% |
| 2023 | -1.10x | $-27.36 Million | $24.84 Million | ▲ +0.8% |
| 2022 | -1.11x | $-31.07 Million | $27.98 Million | ▼ -58.8% |
| 2021 | -0.70x | $-25.96 Million | $37.12 Million | ▼ -237.0% |
| 2020 | -0.21x | $-19.02 Million | $91.66 Million | ▲ +92.4% |
| 2019 | -2.73x | $-41.22 Million | $15.10 Million | ▼ -26.4% |
| 2018 | -2.16x | $-23.65 Million | $10.95 Million | ▲ +48.7% |
| 2017 | -4.21x | $-20.34 Million | $4.83 Million | ▲ +2.3% |
| 2016 | -4.31x | $-61.73 Million | $14.32 Million | ▼ -0.8% |
| 2015 | -4.27x | $-50.29 Million | $11.76 Million | ▼ -43.2% |
| 2014 | -2.99x | $-30.59 Million | $10.25 Million | ▲ +3.6% |
| 2013 | -3.10x | $-18.09 Million | $5.84 Million | ▲ +41.9% |
| 2012 | -5.33x | $-11.16 Million | $2.09 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.